Jun 30, 2000|
Abbott Laboratories: An Attractive Dose?
Abbott Laboratories (India), the 51.5% Indian subsidiary of Abbott USA has practically come back from the dead. The company had reported a loss in 1997-98 but managed to turn around in 1998-99. The current year has seen the company report a 100% jump in pre–tax profits.
The stock however has travelled on an altogether different trajectory over the last one year. In March 1999 the stock was quoting at a price of over Rs 1,400 per share. This was just before the time when the company made a rights issue, in the ratio of 4:25 at a price of Rs 625. It is now available at a price of Rs 408.
Abbott Laboratories USA is a leading healthcare company with over 54,000 employees and a worldwide sales of over $ 12 bn. The company’s leading brands include Biaxin (antibiotic), Hytrin (hypertension), Norvir (anti–AIDS), Zyflo (anti–asthma) and Depakote (for epileptic seizures). Apart from these the company has a lucrative diagnostic portfolio of products too.
Abbott India, is active in the areas of anti–infectives, dermatological (skin infection), anti–diarrhoeal and gastro–intestinal apart from a portfolio of hospital products and nutritional products. The company has introduced Hytrin in India. The product has captured over 55% market share and has been growing at over 50% over the last two years. The company’s Claribid (used in cases of upper respiratory tract infection) also has been growing at over 40% and enjoys a 35% market share.
The company has also been restructuring its operations over the last three years. It closed its Kurla plant and paid of its entire 247 employees. It currently employs around 466 people of which 358 are field staff who form a part of its marketing team. The company also has a wide distribution network with 4 depots, 11 C & F Agents and 1,200 stockists catering to 30,000 retailers.
Abbott outforms projections
The company has outperformed the projections that it had made at the time of the rights issue and can be expected to grow at around 11% in the current year too. If one were to exclude the write off of deferred revenue expenditure, the current stock price implies an earning multiple of around 19 times. The company has already written of the deferred expenditure of Rs 43 m in the current year (the total expenditure to be written off amounted to Rs 65.28 m as at March 31, 1999).
Perhaps, the only grey area is the lack of liquidity in the stock. With 51.5% of the 2.61 m shares with the parent and another 30% with institutions, the liquidity on the counter has always been a problem. The company has announced a stock split of 2 shares of Rs 5 each for every 1 share held which should address the problem to some extent.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
May 30, 2017
US markets decline while other geographies grow in the quarter.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 10, 2017
Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407